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Abstract
Gastric cancer (GC) represents a major public health issue worldwide, being 
the fifth most common cancer and one of the leading causes of death by cancer. 
In 2014, The Cancer Genome Atlas (TCGA) established that tumors positive for 
Epstein-Barr virus (EBV) are considered a specific subtype of GC (EBVaGC). 
Several meta-analyses have shown that EBVaGC represents almost 10% of all gastric 
cancer worldwide, with small differences in the geographic distribution. This tumor 
subtype has a high potential of being clinically relevant and studies have shown that 
it has specific features, a better prognosis, and increased overall survival. In this 
review, we summarize some of the most frequent aspects of EBVaGC, including the 
specific features of this GC subtype, data regarding the potential steps of EBVaGC 
carcinogenesis, and perspectives on treatment opportunities.




Gastric cancer (GC) represents a major public health issue worldwide, being the 
fifth most common cancer and one of the leading causes of death by cancer [1, 2]. 
GC affects more than 1,000,000 people per year and leads to approximately 783,000 
deaths each year, corresponding to 5.7% of new cases and 8.2% of all cancer related 
deaths (Figure 1). Worldwide, GC incidence has a distinct geographic distribution 
pattern [3, 4] (Figure 2). The highest incidence rates are registered in Eastern Asia 
and Central/Eastern Europe, while Northern America and Africa have the lowest 
incidence rates [1, 5].
There seems to exist some ethnic/racial disparities in the distribution of GC 
[6, 7]; nevertheless studies showed that this may be the explained by the different 
expositions to GC risk factors such as dietary, salt intake, and Helicobacter pylori 
infection [5, 8]. Furthermore, despite the worrying high mortality associated with 
GC, the incidence of GC globally has been declining since 1990. This trend is mostly 
due to the falling rates of non-cardia GC, which is explained by the improvement of 




GC classification has been changing according to its anatomical, histological, 
or molecular features without a consensus regarding the best system combining 
prognosis and high practicality in clinical diagnosis [10–16]. For many years, 
Figure 1. 
Estimated number (a) of incident cases and deaths of gastric cancer worldwide and (b) age-standardized rates 
(GLOBOCAN 2018).
Figure 2. 
Gastric cancer age-standardized rate incidence worldwide (GLOBOCAN 2018).
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the anatomical classification was used to distinguish cardia and non-cardia GC, 
which have distinct etiological and epidemiological characteristics [3, 6, 11]. Two 
classification systems that have been used for diagnosis and treatment decisions 
are the Lauren classification and World Health Organization (WHO) classification; 
 nevertheless, the clinical impact is still limited [10, 17].
The Lauren classification divides gastric adenocarcinomas into diffuse, intestinal, 
and intermediate type, which combines cancers with uncommon histology [10, 
18, 19]. There are multiple evidences indicating that the two principal subtypes 
may have distinct tumor development pathways [10, 18]. The intestinal type 
presents specific characteristics such as well/moderate differentiation of cells, loss 
of E-cadherin expression and is associated with H. pylori infection [7, 20]. The 
carcinogenesis model of this subtype is characterized by a progressive model char-
acterized by chronic gastritis and gastric mucosa metaplasia [10]. The diffuse type 
is characterized by poorly differentiated cells with cellular atypia and numerous 
mitotic figures and poorly cohesive structure, and therefore it is more aggressive 
and with worse prognosis [11, 18, 19]. The WHO classification divides GC accord-
ing to the histological features of each subtype: papillary, tubular and mucinous 
adenocarcinomas, poorly cohesive (including signet-ring cell carcinomas), mixed 
carcinomas (with two or more components), and uncommon variants [21, 22].
In 2014, The Cancer Genome Atlas (TCGA) consortium group proposed a clas-
sification of gastric adenocarcinomas into four distinct subtypes based on their 
molecular features, which may have a higher clinical impact in treatment prediction 
and prognosis: (1) microsatellite unstable tumors (MSI), (2) genomically stable 
tumors (GS), (3) tumors with chromosomal instability (CIN), and (4) tumors posi-
tive for Epstein-Barr virus (EBVaGC) [17, 22, 23] (Figure 3). Later in 2018, Hinoue 
et al. described another subtype of GC, characterized by hypermutated status with 
single-nucleotide variants (hypermutated-SNV, HM-SNV) [24, 25]. This system 
seems to have a higher clinical impact in treatment prediction and prognosis when 
compared with previous classification systems [26, 27]. Later, the Asian Cancer 
Research Group (ACRG) has proposed a new classification according to patterns of 
molecular alterations, disease progression, and prognosis: (1) high microsatellite 
instable (MSI-high) tumors, (2) microsatellite stable with epithelial-to-mesenchy-
mal transition (MSS/EMT) phenotype tumors, (3) microsatellite stable with TP53 
Figure 3. 
Essential features of gastric cancer subtypes according to the Cancer genome atlas research network.
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intact (MSS/TP53+), and (4) microsatellite stable with TP53 loss (MSS/TP53-) [16, 
28]. It is possible to obtain a partial correspondence between the TCGA and ACRG 
classifications, although EBV is not specifically included in the ACRG classification, 
EBV infection was frequently observed in the MSS/TP53+ subtype [29].
Additional subtypes of GC have been described based on the TCGA and 
ACRG classifications and specific analysis of different genetic features [29–31]. 
Nevertheless, independently of the classification system, EBV-positive GCs are 
considered to be of better prognosis [26, 27].
1.3 Gastric carcinogenesis and risk factors
Gastric cells’ malignant transformation is a multistep process in which risk 
factors, genetic or epigenetic alterations can be observed [32, 33]. The carcino-
genesis model for the other GC subtypes still remains a challenge for scientists due 
to the different histological subtypes [18, 34, 35]. The most accepted hypothesis 
of gastric carcinogenesis has been described for the intestinal subtype according 
to the Lauren’s classification, and it is characterized by a cascade of progression 
from normal gastric epithelium through chronic gastritis (CG), chronic atrophic 
gastritis (CAG), and intestinal metaplasia (IM), ultimately leading to dysplasia and 
 carcinoma [36, 37].
There are common risk factors for GC that can be subdivided into modifi-
able and non-modifiable. The non-modifiable factors include age, male gender 
and familiar history, and inherited syndromes, such as familial adenomatous 
polyposis (FAP) and Peutz-Jeghers syndrome (PJS), hereditary diffuse gastric 
cancer (HDGC) or Lynch syndrome [7, 38–40]. Host genetic polymorphisms 
have also been described to contribute to an increased risk pattern for GC 
development [41].
The modifiable risk factors can be divided in two major groups: dietary/lifestyle 
influences and infectious agents [39]. Dietary and lifestyle risk factors for GC 
include salt and salted preserved food, fruits and vegetables, tobacco, alcohol and 
body mass index (BMI), and physical activity [38, 42]. Data suggest that high salt 
consumption is responsible for a two-fold increase in the risk of GC development 
when compared to low salt intake, mainly because it induces early atrophic gastritis 
[39, 43]. Conversely, consumption of fresh fruits and vegetables, with vitamins C 
and E, carotenoids, and selenium has been associated with a decreased risk of GC 
in around 20-30% [7, 20]. As in other types of cancer, studies suggest that tobacco 
smoking is responsible for a 1.5-fold increased relative risk of developing GC [7]. 
Despite no explicit association, alcohol consumption is also associated with increase 
in risk of gastric cancer [7, 44]. A meta-analysis study has shown that high body 
mass index (BMI) (>25) increases the risk to develop non-cardia gastric cancer, 
which is 1.4-fold for overweight and two-fold in obese individuals. Conversely, 
regular physical activity seems to be associated with lower risk of GC [39, 45].
H. pylori infection affects around 50% of world population and has been classi-
fied by World Health organization (WHO) as a class I carcinogen being responsible 
for a two-fold increase in the risk of developing non-cardia gastric adenocarcinoma 
[7, 46, 47]. H. pylori contributes to gastric carcinogenesis by inducing chronic 
gastritis that over time may progress to severe atrophic gastritis, which in turn can 
develop to cancer [20, 44]. Other risk factors have been described as contributing 
to increase the risk of persistent H. pylori infection and therefore to GC develop-
ment [48]. The Epstein-Barr virus [49] is another infectious agent accepted as 
associated with gastric carcinogenesis, however, the mechanism of action in gastric 
 carcinogenesis is still unknown [44, 50, 51].
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2. EBV-associated gastric cancer
2.1 Historical background
Epstein-Barr virus [49] is linear, double-stranded DNA virus member of her-
pesviridae family, with a high prevalence worldwide (>90% of adults) [52]. EBV is 
recognized for establishing a latent infection with frequent reactivations and has 
been associated with the development of multiple diseases from infectious mono-
nucleosis to different cancers [52–55]. EBV was the first virus to be recognized as the 
etiological cause of a human cancer, and since 1997, it is included by the International 
Agency for Research on Cancer in the Group-I carcinogen risk factors [56–58]. Indeed, 
EBV has been associated with several human tumors, including Burkitt’s lymphoma, 
Hodgkin’s disease, B cell lymphomas, and also some epithelial neoplasms such as 
nasopharyngeal carcinoma (NPC) or more recently GC [52, 59, 60].
The association between EBV and gastric carcinoma was first described in 
1990, when Burke et al. used a polymerase chain reaction (PCR) technique to 
detect EBV in lymphoepithelioma-like gastric carcinomas, characterized by the 
presence of cells morphologically similar to the undifferentiated nasopharyngeal 
lymphoepithelioma [61]. Later, Shibata and colleagues have demonstrated by in situ 
hybridization that EBV infection was present in gastric carcinoma cells resembling 
lymphoepithelioma but not in reactive lymphoid infiltrate or normal mucosa [62]. 
Additionally, 1 year later, EBV infection was also detected in cases of typical gastric 
adenocarcinoma [62]. Over the past 30 years, GC has been consistently associ-
ated with EBV infection [51, 61, 63, 64] and EBV-associated gastric carcinoma 
(EBVaGC) which is now recognized as one specific subtype of GC [51, 65, 66].
2.2 Epidemiology and clinicopathological characteristics
Several meta-analyses have been attempting to summarize the association of 
EBV with CG development, showing that EBVaGC may represent almost 10% of 
all gastric cancer worldwide [66–74]. A recent meta-analysis with data from over 
20,000 cancer patients within 26 different countries has shown that EBVaGC 
prevalence ranges from 1.69 to 43.75%, with a pooled prevalence of 8.77% (95% CI: 
7.73–9.92%) and a pooled odds ratio (OR) of 18.56 (95% CI: 15.68–21.97) for studies 
with matched pairs and 3.31 (95% CI: 0.95–11.54) for studies with non-matched 
pairs design [72].
In contrast to others EBV-associated malignancies, EBVaGC is a non-endemic 
endemic disease distributed throughout the world. Data analysis showed no signifi-
cant variation within the different world regions (8.21% in Europe, 8.38% in Asia, 
9.51% in America, and 11.9% in Africa); indeed, it is possible to observe similar 
data in countries from Europe, including Portugal (8,4%) [75], Netherlands (7.8%) 
[67], and Denmark (7.6%) [76], and also from Asiatic countries such as South Korea 
(7.8%) [77] and Japan (8.0%) [78]. Nevertheless, it is still possible to observe differ-
ences among countries, and the differential expositions to risk factors are proposed 
as the possible explanation for the variation of EBVaGC prevalence [68, 69]. Indeed, 
some studies suggest that EBVaGC prevalence might be inversely correlated with 
the background incidence of GC [70].
EBVaGC seems to be more prevalent in younger patients and in males than in 
females (almost two-fold more prevalent), which has been a consistent association 
found in several, suggesting a potential association with lifestyle or hormonal factors 
[68, 69, 72, 79–84] (Figure 4). In addition, EBVaGC seems to be more frequently 
found in the proximal stomach and has a moderate to poor degree of differentiation 
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[17, 58, 69, 72, 81, 82, 85–87]. These features are being suggested as potentially 
impacting the overall survival and recurrence of EBVaGC [26, 66, 80, 88], and a study 
with 4599 patients (pooled analysis) showed that EBVaGC has increased the overall 
survival and this is still a controversial topic [80]. One study evaluated the clinical 
significance of the different molecular subtypes of gastric cancer and concluded that 
EBVaGC, independently of the classification system, is of better prognosis [26, 27].
EBV association with gastric cancer was first described in lymphoepithelioma-
like carcinoma also known as carcinoma with lymphoid stroma (GCLS) or medul-
lary carcinomas [61, 88–90]. Recently, it has been described that there are three 
histological subtypes of EBVaGC based on the host cellular immune response status: 
the carcinomas with lymphoid stroma (GCLS), the carcinoma with Crohn’s disease-
like lymphoid reaction (CLR), and the conventional-type adenocarcinoma (CA) 
[91].GCLS is a rare histological subtype of gastric cancer, representing about 1-4% 
of all gastric cancers, of which literature shows that more than 90% of these cases 
are EBV-positive and characterized by poorly differentiated nests of neoplastic 
epithelial cells intermingled with a dense lymphoid proliferation [61, 63, 66, 69, 
90, 92–94]. Nevertheless, literature has been focusing on the characterization of 
non-GCLs EBV-positive gastric cancers. This association remains controversial, and 
while several studies demonstrated a strong EBV association with a diffuse subtype 
[68, 95], others have reported a similar prevalence between intestinal and diffuse 
subtypes [67, 88, 96, 97]. Indeed, one meta-analysis has shown association with a 
diffuse subtype [66, 68], while two other meta-analyses did not find any association 
within histological subtypes [69, 74].
2.3 Diagnosis
The identification of EBVaGC has been performed by the identification of EBV 
transcripts in gastric tissues using in situ hybridization (ISH) by detecting EBV-
encoded small RNAs (EBERs), which are highly expressed in latently EBV-infected 
cells [66, 91]. EBV-associated tumors are defined as monoclonal proliferations of 
carcinoma cells with latent EBV infection, and studies have confirmed that every 
cell from the cancer clone carries the clonal virus genome, suggesting that the virus 
was acquired before the transformation, even though it seems that it is not detected 
in precursor lesions [70, 86, 98].
The detection of EBV by PCR-based methods has been controversial since 
it frequently provides false positive results due to the presence of EBV-positive 
Figure 4. 
Features of Epstein-Barr virus-associated gastric carcinomas.
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lymphocytes in the surrounding tissue, ignoring that it might be absent in the 
tumor epithelial cells [66]. Therefore, EBER-ISH is considered the gold-standard 
method, and a positive EBV-associated case should be considered only if in the 
presence of EBERs in tumor cells and in its absence in the normal surrounding 
tissue [99].
2.4 Carcinogenesis mechanism
During the past decade, several authors have been discussing the mechanism of 
EBV carcinogenesis in GC [68, 100]. EBV is known to enter cells in oropharyngeal 
lymphoid tissue by the recognition/interaction with CR2/CD21 on the surface of 
B-lymphocytes that interact with EBV envelope glycoprotein gp350 [101, 102]. How 
and when EBV gets into gastric epithelial cells remains unclear, and it has been sug-
gested that it can be either by cell-to-cell with B-lymphocytes recruited in inflam-
matory processes of gastric mucosa or through direct entry into the gastric epithelia 
[103]. This mechanism is not well understood and further studies should be made 
to establish if the recruitment of EBV-infected lymphoid cells might be the explana-
tion for the infection and subsequent transformation of gastric epithelium.
Overall, literature suggests that EBV participates on gastric carcinogenesis 
by both direct and indirect mechanisms: infecting epithelial cells and establish-
ing a latent program in which a restrict profile of latent proteins/transcripts are 
expressed; and/or promoting a chronic inflammatory response contributing to 
tissue damage and cancer progression [104, 105].
Previous studies regarding the detection of EBV in premalignant lesions of gas-
tric cancer are extremely controversial [106–109] and the majority report its pres-
ence mainly in dysplasia and atrophic gastritis adjacent to tumors [87, 105–114]. A 
recent cross-sectional study from the North Region of Portugal showed no evidence 
of EBV infection in both dysplasia and early gastric carcinomas [75]. The absence 
of EBER transcripts in superficial gastric neoplastic lesions may suggest that EBV 
infection is a late event in gastric carcinogenesis [75]. Hence, it is still important to 
clarify the moment of EBV infection in gastric cells and if it acts as the initiator of 
carcinogenesis or as a promoter after prior modifications of gastric cells.
EBVaGCs are EBV-associated epithelial malignancies and therefore the mecha-
nism of viral carcinogenesis might be similar to the observed in NPC. Two in vitro 
studies demonstrated that nasopharyngeal cells need to have some genetic change 
prior to be susceptible of EBV transformation [115, 116]. In fact, preexisting genetic 
events, mainly cyclin D1 overexpression and p16 mutations, seem to support the 
establishment of stable EBV infection and transformation in NPC epithelium [115, 
116]. A recent publication suggests that EBV coordinates with somatic gene muta-
tions in order to induce the carcinogenesis process in gastric epithelial cells [117]. 
This mechanism suggests that high-frequency mutations, such as in PIK3CA and 
ARID1A, are essential for the transformation of normal gastric cells into susceptible 
cells, which are more likely to be infected and transformed by EBV [117]. In addi-
tion, after infection, amplification of PD-L1 and PD-L2 are thought to increase the 
progression and immune evasion of transformed cells [117].
Some studies have been suggesting a possible interaction between H. pylori 
and EBV in gastric cancer development. Minoura-Etoh et al. observed a possible 
antagonism effect between H. pylori and EBV, showing that reactive products from 
H. pylori seem to induce EBV reactivation from latently in infected gastric epithe-
lial cells, which would avoid the EBV transformation of gastric cells in the same 
areas of H. pylori colonization [118]. H. pylori seems to preferentially colonize the 
antral region, while EBV is more frequently found in the upper third and middle of 
stomach, suggesting a possible antagonism of EBV and H. pylori in gastric mucosa 
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[119–121]. By contrast, two other studies have suggested that H. pylori may con-
tribute for EBV-associated gastric carcinogenesis by causing gastritis that perhaps 
might recruit EBV-carrying lymphocytes to the stomach wall, where the virus 
could be induced to replicate and infect gastric epithelial cells [122, 123]. Moreover, 
the gastric inflammation may also promote a cytokine-rich microenvironment, 
 supporting a clonal growth of EBV-infected epithelial cells [110].
EBV establishes a latent infection allowing it to be maintained inside cells and to 
use the host machinery to express their own genes, regulating the cell behavior and 
escaping the immune system recognition [124, 125]. EBV latency is characterized 
by the expression of different viral proteins such as EBV nuclear antigens (EBNAs 
1, 2, 3A, 3B, 3C, and EBNA-LP), EBV-encoded small RNAs (EBERs) 1 and 2, latent 
membrane protein (LMP 1, 2A, and 2B), and microRNAs from BamHI-A rightward 
transcripts, known as BARTs [58]. Depending on the infected cell type and differen-
tiation status, different proteins are expressed, originating different latency profiles 
[124–126] (Table 1). Literature refers that the majority of EBVaGC cases show a 
latency II-like pattern (44%), defined by expression of EBNA1, EBERs, BARF1, and 
LMP2A genes, and latency I (42.9%) restricted to EBNA1, EBERs, and BARTs expres-
sion [75, 127]. The fact that different latency states seem to be associated to different 
malignancies explains the different mechanism of carcinogenesis on which EBV is 
involved and is thought to be important for EBVaGC characterization [124–126].
The function of the different EBV latent proteins has been widely studied. 
Each protein seems to have a significant role for the EBV cell cycle and transforma-
tion: EBNA1, expressed in every single infected cell, acts as a transcription factor 
responsible for the episomal maintenance, DNA replication, and indirectly to cell 
transformation [56, 65, 128, 129]; EBNA2 is early expressed in recently infected B 
cells, playing a crucial role in these cells’ immortalization through the transcrip-
tion of both viral and host genes [56, 130]; the EBNA3 protein family activates 
the transcription of cellular and viral genes, leading to the disruption of cell cycle 
checkpoints on different levels [56, 130]; LMP1, the major EBV oncogene, is essen-
tial for B-lymphocytes transformations, induction of apoptotic genes, epithelial cells 
transformations, and invasiveness and avoids cells apoptosis by different pathways 
[56, 125, 129, 131]; LMP2 essentially avoids the activation of the EBV lytic cycle in 
B-lymphocytes and modulates epithelial cell growth [56, 125, 129]; and EBER’s role is 
not yet well understood but is thought to contribute to B cell transformation, acting 
as signaling and transcription factor regulators [56, 130]. EBV also encodes around 
EBNA1 EBNA2 EBNA3 LMP1 LMP2 EBERs Malignancies
Latency I x x Burkitt’s lymphoma 
and gastric cancer







x x x Gastric cancer





EBV-associated diseases’ latency profiles.
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40 miRNAs, which are known to bind and possibly participate in the regulation 
of hundreds of cellular and viral transcripts, some of them being involved in cell 
survival [56, 130]. These miRNAs can be referred as BHRF1 and BARTs, depending 
on its localization on the viral genome [130]. BHRF1 role is not very understood yet 
but some results suggest that BHRF1 miRNAs and proteins cooperate to control cell 
cycle initiation and apoptosis during primary infection [130]. Regarding BARTs, 
they are described as contributing to EBV-induced carcinogenesis by downregulating 
host genes, such as tumor suppressors and pro-apoptotic genes, including several cell 
growth and cell cycle-related [129, 130]. Nevertheless, is still important to clarify the 
coordination of virus and host cell in gastric cancer carcinogenesis.
2.5 Molecular features of EBVaGC
EBVaGC has some distinctive features in terms of genome alterations [17, 66, 132] 
(Figure 4). EBVaGC has been reported to have the most extensive CpG island meth-
ylation (human and viral genomes) than in any other tumor. This is described as EBV-
CIMP (CpG island methylator phenotype) and includes genes related to cell cycle 
regulation (p14ARF, p15, p16INK4A, and p73), DNA repair (hMLH1, MGMT and 
GSTP1), cell adhesion and metastases (CDH1, TIMP1, and TIMP3), apoptosis (DAPK 
and bcl-2), and signal transduction (APC, PTEN, and RASSF1A) [17, 133–135].
EBVaGC is characterized by mutations in the PIK3CA gene and amplification of 
9p24.1 locus containing JAK2, CD274, PDCD1LG2, and ERBB2 which contribute to 
altered proliferation, deregulation of apoptosis, and immune suppression and eva-
sion [17, 136]. PIK3CA gene, which encodes phosphatidyl inositol-3-kinase (PIK3), 
has been consistently shown to be mutated in EBVaGC [17]. This protein is an impor-
tant component of PI3K/Akt/mTOR signaling pathway and regulates several cellular 
processes such as apoptosis escape, cell growth, and proliferation [137]. Mutations 
in PIK3CA are common in several tumors, nevertheless in EBVaGC, about 80% are 
non-silent mutations and the vast majority are not located in the hot-spot sites but 
are dispersed in the gene sequence [17, 137]. EBVaGC has also been described as 
having mutations in other genes such as ARID1A and BCOR [17, 66, 132]. Interesting, 
TP53 mutations that occur in the majority of gastric tumors are rare in EBVaGC, nev-
ertheless a study has shown that these tumors seem to present a lower level of TP53 
mRNA and a higher level of p53 protein when compared with EBV-negative cancers, 
which increases the interest in studying the p53 pathway regulation [17, 138].
EBVaGC has also been described to have higher levels of programmed death 
ligands 1 and 2 (PD-L1/2) enriched with CD8 + tumor-infiltrating lymphocytes 
(TILs) and with high expression of immunogenic pathways [25, 139, 140]. 
Indeed, this is considered a highly immunogenic tumor with a great potential for 
 immunotherapy [24].
2.6 Treatment options for EBVaGC
The unique molecular features of EBVaGC have gained interest in the past years, 
especially for the potential impact of targeted drugs since preclinical data have 
shown that EBVaGC is resistant to current chemotherapy [141].
PD-L1 overexpression has been consistently considered a marker for EBVaGC 
and MSI-high GC cases [142, 143]. Several PD-1 targeted drugs available on 
the market are being studied for its use in several cancers, including GC [141]. 
Pembrolizumab, a PD-1 antibody, was the first to be approved by the Food and 
Drug Administration (FDA) for use in recurrent MSI-high GC after a good rate 
response in several clinical trials (NCT03257163, NCT02589496) [142, 144–146]. 
Pembrolizumab has also been used for the treatment of EBV-positive T cell 
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lymphomas [147] and trials with EBVaGC are showing promising results [142]. 
Several clinical trials that include EBVaGC are testing other PD-1 target drugs, such 
as nivolumab (NCT02951091) or avelumab (NCT01772004), or by using CRISPR-
Cas9-mediated PD-1 knockout EBV cytotoxic T cells (NCT03044743) [148–150]. 
Despite this, there are some controversial points regarding PD-L1 standardization 
and cutoffs, and the results from these studies point for an important role as a 
therapeutical target for GC, particularly in those with MSI-high or EBV. Indeed, 
EBV is now considered a biomarker for GC and the clear identification of EBVaGC 
in clinical series will contribute for the implement of better treatment strategies.
Literature shows that EBaGC has frequent PIK3CA mutations [17] and is 
thought to impact negatively the outcome of disease; nevertheless, the impact 
on the evolution of these cancers is still to understood [151–153]. PI3K/AKT/
mTOR pathway inhibitors have been used as new therapeutical options in cancer, 
especially mTOR inhibitors such as everolimus, which are used in the phase III 
GRANITE-1 study (NCT00879333) for advanced GC with potential interest. More 
recently, PI3K inhibitors such as buparlisib (BKM120) have been tested for use in 
solid tumors [154, 155], and alpelisib has been tested for use as a potential thera-
peutical agent for gastric cancer [156]. There are a lot of PI3K/AKT/mTOR pathway 
inhibitors being used in GC clinical trials, and despite not being directed to EBVGC, 
a potential impact in this specific subgroup is expected.
Another important feature with potential therapeutical interest is the epigenetic 
changes of EBVaGC. It is known that epigenetic changes are reversible and therefore 
many de-methylating agents are been studied in cancer treatment. A few studies 
have reported on the impact of 5-azacitidine or trichostatin A in the activation of 
EBV lytic phase in EBVaGC cell lines, leading to the lysis of tumor cells [157–160]. 
Despite the potential interest, it is important to clearly understand the mechanisms 
of EBV lytic phase activation using de-methylating agents.
3. Conclusions
EBV has been consistently associated with GC development for almost 30 years 
until in 2014, when The Cancer Genome Atlas Research Network recognized 
EBVaGC as a specific subtype of GC. Overall, EBVaGC represents almost 10% of all 
gastric cancer worldwide with a prevalence variation according to geographic and 
risk factors exposition. EBVaGC is more prevalent in males and younger patients 
and is frequently found in the proximal stomach. These tumors have a moder-
ate to poor degree of differentiation and are characterized by a high content of 
CD8 + tumor-infiltrating lymphocytes and high expression of PD-L1 and PD-L2 
and are therefore of great potential for immunotherapy. Indeed, EBVaGC seems to 
has a better prognosis and increased overall survival.
EBVaGC has distinctive molecular features: (1) extensive CpG island meth-
ylation (human and viral genomes) being described as EBV-CIMP (CpG island 
methylator phenotype); (2) mutations in PIK3CA, ARID1A, and BCOR genes; (3) 
amplification of 9p24.1 locus containing JAK2, CD274, PDCD1LG2, and ERBB2; 
(4) absence of TP53 mutations; and (5) a microsatellite stable (MSs) phenotype. 
The development of therapeutical approaches directed to these specific molecular 
features (anti-PD1, PI3K/AKT/mTOR pathway inhibitors, or demethylating drugs) 
is expected to impact the GC management significantly.
In sum, EBVaGC is a specific subtype of GC, presenting special clinical and 
pathological characteristics that could be used for the development new potential 
therapeutical approaches, making this an important topic for the future of gastroin-
testinal tumors.
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